Hira Pharma Distributors Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 16-11-2024
- Paid Up Capital ₹ 1.00 M
as on 16-11-2024
- Company Age 30 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.82 Cr
as on 16-11-2024
- Satisfied Charges ₹ 4.00 Cr
as on 16-11-2024
- Revenue -60.51%
(FY 2023)
- Profit -15.46%
(FY 2023)
- Ebitda -86.61%
(FY 2023)
- Net Worth 3.28%
(FY 2023)
- Total Assets -9.74%
(FY 2023)
About Hira Pharma Distributors
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹1.82 Cr. The company has closed loans amounting to ₹4.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sunil Tulsani, Komal Tulsani, and Divya Tulsani serve as directors at the Company.
- CIN/LLPIN
U24239MH1994PTC077477
- Company No.
077477
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Mar 1994
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Hira Pharma Distributors?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sunil Tulsani  | Director | 31-Mar-1994 | Current |
| Komal Tulsani | Director | 20-Oct-2018 | Current |
| Divya Tulsani | Director | 20-Oct-2018 | Current |
Financial Performance of Hira Pharma Distributors.
Hira Pharma Distributors Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 60.51% decrease. The company also saw a substantial fall in profitability, with a 15.46% decrease in profit. The company's net worth moved up by a moderate rise of 3.28%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hira Pharma Distributors?
In 2023, Hira Pharma Distributors had a promoter holding of 24.10% and a public holding of 75.90%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 23 Aug 2019 | ₹1.77 Cr | Open |
The Kalyan Janata Sahakari Bank Limited Creation Date: 01 Aug 2003 | ₹0.50 M | Open |
Others Creation Date: 20 Oct 2001 | ₹4.00 Cr | Satisfied |
How Many Employees Work at Hira Pharma Distributors?
Unlock and access historical data on people associated with Hira Pharma Distributors, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hira Pharma Distributors, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hira Pharma Distributors's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
